CA3174172A1 - Compositions et methodes de traitement du cancer - Google Patents

Compositions et methodes de traitement du cancer Download PDF

Info

Publication number
CA3174172A1
CA3174172A1 CA3174172A CA3174172A CA3174172A1 CA 3174172 A1 CA3174172 A1 CA 3174172A1 CA 3174172 A CA3174172 A CA 3174172A CA 3174172 A CA3174172 A CA 3174172A CA 3174172 A1 CA3174172 A1 CA 3174172A1
Authority
CA
Canada
Prior art keywords
seq
lrp2
dsrna
rnai agent
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174172A
Other languages
English (en)
Inventor
David J. ELZI
William E. Bauta
Vivienne I. Rebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioaffinity Technologies Inc
Original Assignee
Bioaffinity Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/359,905 external-priority patent/US20230035774A1/en
Application filed by Bioaffinity Technologies Inc filed Critical Bioaffinity Technologies Inc
Publication of CA3174172A1 publication Critical patent/CA3174172A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3174172A 2021-06-28 2022-01-26 Compositions et methodes de traitement du cancer Pending CA3174172A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/359,905 2021-06-28
US17/359,905 US20230035774A1 (en) 2018-12-27 2021-06-28 Compositions and Methods for Treating Cancer
PCT/US2022/013908 WO2023277959A1 (fr) 2021-06-28 2022-01-26 Compositions et méthodes pour traiter le cancer

Publications (1)

Publication Number Publication Date
CA3174172A1 true CA3174172A1 (fr) 2023-07-26

Family

ID=84692027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174172A Pending CA3174172A1 (fr) 2021-06-28 2022-01-26 Compositions et methodes de traitement du cancer

Country Status (4)

Country Link
EP (1) EP4363577A1 (fr)
CN (1) CN117897482A (fr)
CA (1) CA3174172A1 (fr)
WO (1) WO2023277959A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113508175A (zh) * 2018-12-27 2021-10-15 生物阿非尼提科技公司 用于治疗癌症的组合物和方法

Also Published As

Publication number Publication date
EP4363577A1 (fr) 2024-05-08
CN117897482A (zh) 2024-04-16
WO2023277959A1 (fr) 2023-01-05

Similar Documents

Publication Publication Date Title
CN107980062B (zh) 用于靶向亨廷汀mRNA的寡核苷酸化合物
US11066667B2 (en) Organic compositions to treat APOC3-related diseases
US20220170025A1 (en) Compositions and methods for inhibiting gene expression in the central nervous system
JP2022103192A (ja) タウ発現を調節するための組成物
JP6577073B2 (ja) ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物
EP3394259B1 (fr) Compositions et méthodes pour diminuer l'expression de tau
US10059949B2 (en) Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3
CA3020487A1 (fr) Traitement de la fibrose pulmonaire idiopathique a l'aide de complexes d'arn qui ciblent le facteur de croissance du tissu conjonctif
JP2011516094A (ja) 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
EP3272868A1 (fr) Compositions organiques pour traiter des maladies associées à kras
CN114375194A (zh) 血管生成素样7（angptl7）相关疾病的治疗
US20230357774A1 (en) Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
CA2860676A1 (fr) Compositions organiques pour traiter des maladies associees a la beta-catenine
CN113811311A (zh) 用于组织特异性apoe调节的寡核苷酸
US20240043837A1 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
JP2022031642A (ja) アンチセンスオリゴヌクレオチド
WO2017135397A1 (fr) Oligonucléotide antisens destiné à supprimer l'expression du facteur du complément b
AU2014327809B2 (en) Notch 1 specific sirna molecules
CA3163139A1 (fr) Compositions et methodes pour le traitement du cancer
CA3174172A1 (fr) Compositions et methodes de traitement du cancer
US20230035774A1 (en) Compositions and Methods for Treating Cancer
Wang Poly (ethylene) Glycol-Based Bottlebrush Polymers as Nanocarriers for Oligonucleotide Therapeutics: Design, Synthesis, and Applications
JP2024002985A (ja) 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法
CN118043462A (zh) 用于避免脱靶效应的方法和组合物